upadacitinib 1 MG per 1 ML Oral Solution

RxCUI: 2681015
RxNorm name: upadacitinib 1 MG per 1 ML Oral Solution
Display name: upadacitinib 1 MG per 1 ML Oral Solution
Full name: upadacitinib 1 MG per 1 ML Oral Solution
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:38:51

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Rinvoq	UPADACITINIB	AbbVie Inc.	2966aec7-2ef0-923c-d8ff-fe1a957bf095	2026-06-30	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2681015

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
2966aec7-2ef0-923c-d8ff-fe1a957bf095	upadacitinib 1 MG per 1 ML Oral Solution	SY	100	These highlights do not include all the information needed to use RINVOQ / RINVOQ LQ safely and effectively. See full prescribing information for RINVOQ / RINVOQ LQ . RINVOQ ® (upadacitinib) extended-release tablets, for oral use RINVOQ ® LQ (upadacitinib) oral solution Initial U.S. Approval: 2019	20251023
2966aec7-2ef0-923c-d8ff-fe1a957bf095	upadacitinib 1 MG in 1 mL Oral Solution	PSN	100	These highlights do not include all the information needed to use RINVOQ / RINVOQ LQ safely and effectively. See full prescribing information for RINVOQ / RINVOQ LQ . RINVOQ ® (upadacitinib) extended-release tablets, for oral use RINVOQ ® LQ (upadacitinib) oral solution Initial U.S. Approval: 2019	20251023
2966aec7-2ef0-923c-d8ff-fe1a957bf095	upadacitinib 1 MG/ML Oral Solution	SCD	100	These highlights do not include all the information needed to use RINVOQ / RINVOQ LQ safely and effectively. See full prescribing information for RINVOQ / RINVOQ LQ . RINVOQ ® (upadacitinib) extended-release tablets, for oral use RINVOQ ® LQ (upadacitinib) oral solution Initial U.S. Approval: 2019	20251023